MEDICLIN Aktiengesellschaft

XTRA:MED Stock Report

Market Cap: €121.6m

MEDICLIN Future Growth

Future criteria checks 3/6

MEDICLIN is forecast to grow earnings and revenue by 63.2% and 0.7% per annum respectively.

Key information

63.2%

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth27.5%
Revenue growth rate0.7%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Nov 2024

Recent future growth updates

Recent updates

Pinning Down MEDICLIN Aktiengesellschaft's (ETR:MED) P/S Is Difficult Right Now

Mar 29
Pinning Down MEDICLIN Aktiengesellschaft's (ETR:MED) P/S Is Difficult Right Now

Here's Why MEDICLIN (ETR:MED) Has A Meaningful Debt Burden

Oct 27
Here's Why MEDICLIN (ETR:MED) Has A Meaningful Debt Burden

MEDICLIN (ETR:MED) Has Debt But No Earnings; Should You Worry?

May 19
MEDICLIN (ETR:MED) Has Debt But No Earnings; Should You Worry?

MEDICLIN (ETR:MED) Has Debt But No Earnings; Should You Worry?

Feb 18
MEDICLIN (ETR:MED) Has Debt But No Earnings; Should You Worry?

MEDICLIN's (ETR:MED) Stock Price Has Reduced 44% In The Past Three Years

Dec 07
MEDICLIN's (ETR:MED) Stock Price Has Reduced 44% In The Past Three Years

Earnings and Revenue Growth Forecasts

XTRA:MED - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202676322N/AN/A1
12/31/202575219N/AN/A1
12/31/202473016N/AN/A1
9/30/2024766-114588N/A
6/30/2024764-153878N/A
3/31/2024772-63878N/A
12/31/2023762-114078N/A
9/30/2023752201750N/A
6/30/2023734121648N/A
3/31/20237237939N/A
12/31/20227199935N/A
9/30/2022713113557N/A
6/30/2022716194664N/A
3/31/202270196581N/A
12/31/202168416582N/A
9/30/2021662-96482N/A
6/30/2021662-146382N/A
3/31/2021652-1698120N/A
12/31/2020662-993119N/A
9/30/2020674-179111N/A
6/30/2020669-267108N/A
3/31/202068052973N/A
12/31/2019680102570N/A
9/30/201966521260N/A
6/30/20196654-148N/A
3/31/20196617-1532N/A
12/31/20186518-1828N/A
9/30/20186390-1032N/A
6/30/20186354N/A27N/A
3/31/20186245N/A26N/A
12/31/20176154N/A20N/A
9/30/201760919N/A19N/A
6/30/201759914N/A23N/A
3/31/201759115N/A25N/A
12/31/201658317N/A30N/A
9/30/201658217N/A29N/A
6/30/201657019N/A33N/A
3/31/201656117N/A32N/A
12/31/201555517N/A31N/A
9/30/201555013N/A30N/A
6/30/201554612N/A28N/A
3/31/201554211N/A31N/A
12/31/20145389N/A32N/A
9/30/20145297N/A27N/A
6/30/20145254N/A20N/A
3/31/20145232N/A20N/A
12/31/2013515-3N/A10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MED is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: MED is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MED is expected to become profitable in the next 3 years.

Revenue vs Market: MED's revenue (0.7% per year) is forecast to grow slower than the German market (5.6% per year).

High Growth Revenue: MED's revenue (0.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MED's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y